Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation

Condition:   Leukemia Intervention:   Biological: IM19 CAR-T Sponsor:   Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials